SUZHOU, China, Nov. 7, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the Company will present one of its autoimmune and inflammation pipeline assets, CS2015 (OX40L/TSLP bispecific antibody), in the format of an ePoster plus an on-site oral presentation at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). ACAAI is one of the most influential academic conferences in the fields of allergies, asthma, and immunology, attracting experts and scholars around the world to discuss the latest scientific advancements. This marks the first presentation of CS2015 at an international academic conference. The full content of the abstract and eposter is now officially available on the ACAAI website.

Key highlights of the presentation:

CS2015 features an asymmetric molecular design that simultaneously targets OX40L and TSLP, two clinically validated critical regulators of type 2 inflammation. The molecule incorporates an engineered Fc region with reduced binding affinity for FcγR, which extends its in vivo half-life and optimizes its pharmacokinetic (PK) profile to support long-term dosing intervals. CS2015 also exhibits excellent molecular stability, facilitating the development of high-concentration subcutaneous formulations. Its strong developability profile further supports high-yield and scalable manufacturing.

1.      Dual Blockade:

CS2015 lead molecule demonstrated potent inhibition of OX40L/OX40 and TSLP/TSLPR downstream signaling:

• CS2015 potently interrupted the engagement of hOX40L on hOX40 reporter cells and hTSLP on hTSLPR/IL-7Rα reporter cells, respectively;
• The blocking activities of CS2015 were comparable to those of benchmark (parental) antibodies, with single or sub nanomolar IC50s.

2.      Robust Inhibition of Inflammatory Responses:

CS2015 lead molecule inhibited the release of inflammatory cytokines from primary CD4+ T cells stimulated by TSLP/OX40L and suppressed TSLP-induced release of TARC (CCL17) in human monocytes and peripheral blood mononuclear cells (PBMC).

3.      Early Signs of Efficacy:

CS2015 demonstrated potent disease control activities in Atopic Dermatitis (AD) model with OX40 and TSLP humanized mice. In MC903-induced AD models, CS2015 lead molecule:

• Rapidly reduced skin lesion severity including ear and epidermal thickening;
• Decreased immune cells, especially mast cells infiltration;
• Reduced itch events.

4.      Durability Advantage:

CS2015 demonstrated superb PK profiles in Non-Human Primate (NHP), supporting long-term dosing intervals:

• CS2015 lead molecule K19LS exhibited a mean half-life of 21 days (504.6 hours, Subcutaneous [SC]) and 25.7 days (617.6 hours, Intravenous [IV]);
• K19LS had a clearance rate of 2.4 (SC) and 2.7 (IV) ml/day/kg, and was well-absorbed, with outstanding bioavailability.

5.      Outstanding drug-like properties:

Beyond the data shown in the poster, CS2015 further demonstrated:

• Outstanding accelerated stability under high-temperature stress (40°C);
• Low viscosity (scored at only 3.7 for a 100 mg/ml solution), promising for subcutaneous injection at high-concentration;
• Potent efficacy in the intranasal OVA/TSLP-induced asthma model by decreasing the secretion of IL-4, CCL17, IgE, etc., and alleviating pulmonary pathological changes.

CStone will further advance the development of CS2015 to treat Th2 cell-mediated inflammation diseases, including AD, asthma, hidradenitis suppurativa (HS), chronic obstructive pulmonary disease (COPD), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), etc.

The presentation schedule is as follows:
Title: CS2015 a TSLP/OX40L Bispecific Antibody as a Potential Novel Therapeutic Agent for Type 2 Inflammation Diseases
Presentation Type: ePoster display & 15-min on-site oral presentation (ePoster ID: R377)
Abstract ID: 8079
Date & Time: Friday, November 7, 3:05 PM ET
Location: ePoster Area of the West Exhibit Hall, Monitor 22
*The abstract and ePoster have been officially available on ACAAI website: https://epostersonline.com/acaai2025/.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com. 

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

LUXEMBOURG, Nov. 7, 2025 /PRNewswire/ — Breakwater Energy Holdings S.à r.l. (the “Issuer”) today announced that it has priced an offering (the “Offering”) of $725,000,000 aggregate principal amount of its 9¼% Senior Secured Notes due 2030 (the “Notes”).

The Issuer intends to use the proceeds from this Offering to (1) repay amounts outstanding related to the acquisition of the Issuer’s ordinary stock of Repsol E&P S.à r.l. (“Repsol E&P”) and (2) pay related fees and expenses. 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. 

About Breakwater Energy

The Issuer, a company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, is the 25% owner of Repsol E&P. Repsol E&P is the parent company of the group comprising Repsol E&P and its consolidated subsidiaries (the “Repsol E&P Group”). The Repsol E&P Group’s upstream activities include hydrocarbon exploration, development, production, carbon capture and storage and commercialization activities. Repsol E&P built the Repsol E&P Group’s international presence over decades with the objective of delivering resilient, hydrocarbon production that is efficient, profitable and cash flow generating.

About EIG

EIG is a leading institutional investor in the global energy and infrastructure sectors with $23.8 billion under management as of June 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.3 billion to the energy sector through 420 projects or companies in 44 countries on six continents. EIG’s clients include many of the leading pension plans, insurance companies, endowments, foundations and sovereign wealth funds in the U.S., Asia and Europe. EIG is headquartered in Washington, D.C. with offices in Houston, London, Sydney, Rio de Janeiro, Hong Kong and Seoul.

Media contact:
FGS Global
Kelly Kimberly / Brandon Messina
+1 212-687-8080
EIG@fgsglobal.com

Cautionary Statement
The Offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security nor shall there be any offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

The Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes are being offered and sold in the United States only to persons who are both (i) qualified institutional buyers in accordance with Rule 144A under the Securities Act and (ii) qualified purchasers as defined in Section 2(A)(51)(A) of the U.S. Investment Company Act of 1940 and to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act.

This announcement is only addressed to and directed at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments (being investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”)), (iii) fall within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial Promotion Order, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any Notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). The Notes will only be available to relevant persons and this announcement must not be acted on or relied on by anyone who is not a relevant person. Any offer of the Notes in the UK will be made pursuant to an exemption under the Financial Services and Markets Act 2000 and Regulation (EU) 2017/1129 (the “Prospectus Regulation”) as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 from the requirement to publish a prospectus for offers of securities.

The offer and sale of the Notes in the European Economic Area (the “EEA”) will be made pursuant to an exemption under the Prospectus Regulation from the requirement to produce a prospectus for offers of securities.

Manufacturer target market (MIFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail investors in the EEA or UK.

This press release may include “forward looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward looking statements can be identified by the use of forward looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will” or “should” or, in each case, their negative, or other variations or comparable terminology. These forward looking statements include all matters that are not historical facts and include statements regarding the Issuer or its affiliates’ intentions, beliefs or current expectations concerning, among other things, the Offering.

By their nature, forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward looking statements are not guarantees of future performance and that the Issuer and its affiliates’ actual results of operations, financial condition and liquidity, and the development of the industry in which they operate may differ materially from those made in or suggested by the forward looking statements contained in this press release. In addition, even if the Issuer or its affiliates’ results of operations, financial condition and liquidity, and the development of the industry in which the Issuer operates are consistent with the forward looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you should not rely on forward looking statements as a prediction of actual results. 

• EQT signs SPA to invest in Douzone Bizon, a provider of ERP and software solutions in South Korea
• EQT plans to acquire a 37.6% stake in Douzone Bizon, including shares held by majority shareholder, Chairman Young-woo Kim, and other major shareholders, subject to customary regulatory approvals including merger control clearance and licensing authorization from the Ministry of Trade, Industry, and Resources
• The investment reflects EQT’s continued, long-term commitment to the South Korean market and underscores the firm’s momentum across Asia this year

SEOUL , Nov. 7, 2025 /PRNewswire/ — EQT announced today that a vehicle managed by EQT (“EQT”) has signed a share purchase agreement (SPA) under which EQT will invest approximately USD 930 million (KRW 1.3 trillion) into Douzone Bizon (the “Company”; ticker symbol: KRX 012510), a provider of enterprise resource planning (ERP) and business software solutions in South Korea. The stake consists of the entire 23.2% held by Chairman Young-woo Kim and 14.4% held by affiliates of Shinhan Financial Group. Upon completion, the transaction would result in EQT holding 37.6% of shares outstanding (34.8% based on shares issued, including treasury shares) in Douzone Bizon.

Founded in 1991, Douzone Bizon develops and offers enterprise software solutions to small- and medium-sized enterprises in South Korea. Its suite of cloud and software offerings extend beyond core ERP into tax, accounting, compliance, and communication services. For EQT’s acquisition of Douzone Bizon to proceed, government approvals are required – including merger clearance from the Korea Fair Trade Commission and licensing authorization from the Ministry of Trade, Industry, and Resources.

This transaction represents EQT’s commitment to bringing its global expertise in digital transformation and enterprise solutions to the Korean market, with a focus on long-term value creation. Known for its purpose-driven investment approach, EQT typically implements management enhancement strategies over a period of at least five years. In line with this philosophy, the firm is expected to take a long-term perspective with Douzone Bizon – prioritizing internal investments and business strengthening in the early stages over short-term profitability.

With this transaction, BPEA Private Equity Fund IX is expected to be 5-10 percent invested (including closed and/or signed investments, announced public offers, if applicable, and less any expected syndication) based on hard cap fund size and subject to customary regulatory approvals.

Contact

EQT Press Office, press@eqtpartners.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-to-invest-usd-930-million-in-douzone-bizon–a-leading-provider-of-erp-and-software-solutions-in-,c4263128

The following files are available for download:

Advancement to second stage of DARPA Quantum Benchmarking Initiative validates promise of Silicon Quantum Computing’s in-house manufacturing for building quantum computers using engineered atoms in silicon

SYDNEY, Nov. 7, 2025 /PRNewswire/ — Silicon Quantum Computing (SQC), a leader in quantum computing and quantum machine learning, today announced its selection by the Defence Advanced Research Projects Agency (DARPA) to progress to the next stage of the Quantum Benchmarking Initiative (QBI). The news follows SQC’s award of a DARPA QBI Stage A contract in April 2025.

The QBI assesses the feasibility of building a useful quantum computer by 2033. Successful QBI participants will advance through three stages. Stage A required SQC to provide in-depth description and analysis of their utility-scale quantum computer with a path to near-term realization and where value exceeds costs incurred in development and deployment.

During Stage A, the DARPA team worked closely alongside SQC to rigorously validate SQC’s unique and leading approach to building a commercial scale quantum computer within silicon. The key features of the 14|15 platform – in-house atomic precision manufacturing and exceptional qubit quality – helped secure SQC’s progression. SQC’s mission is to, in a matter of years, deliver quantum computers capable of accurately and efficiently running algorithms that will shift the landscape of global cybersecurity, materials science and artificial intelligence.

Stage B, which begins immediately, will see SQC develop a detailed research and development roadmap through to 2033. This will include technical requirements and highly detailed designs.

SQC’s Founder and CEO, Michelle Simmons, said, “DARPA’s rigorous process of assessing and validating the different approaches to building quantum computers helps to separate the signal from the noise in our industry.”

“We are proud to be selected for Stage B and to have been awarded a next-stage contract. Our ongoing participation in QBI allows us to accelerate the delivery of increasingly useful universal quantum computers, while continuing to deliver value and advantage to customers today through application-specific quantum systems.”

The adoption of quantum computing solutions is accelerating across industries. SQC is dedicated to delivering value and advantage to customers today who engage with their atomically engineered Quantum Machine Learning chips, and their universal quantum computing systems that have demonstrated world leading algorithmic fidelity.

“SQC’s in-house manufacturing of atoms engineered with atomic precision in silicon continues to pay dividends. With DARPA’s scientific recognition and wider customer results SQC will continue to bring the quantum future closer.” added SQC Chair and former ARM CEO Simon Segars.

About Silicon Quantum Computing

Silicon Quantum Computing (SQC) is at the forefront of global efforts to build a commercial-scale quantum computer.

SQC uses machines and processes that allow them to see and control matter atom-by-atom. This ultra-precise approach is crucial to realising the quantum future and has already resulted in the company achieving the highest reported fidelities on quantum algorithms of any company. Owning their QPU manufacturing also means that SQC can design, produce and test new designs every week alongside delivering quantum machine learning and quantum chemical simulation systems today.

For more information, visit www.sqc.com.au